Eurocine Vaccines Overview

  • Founded
  • 1999
Founded
  • Status
  • Public
  • Employees
  • 4
Employees
  • Stock Symbol
  • EUCI
Stock Symbol
  • Share Price
  • $0.47
  • (As of Friday Closing)

Eurocine Vaccines General Information

Description

Eurocine Vaccines AB focuses on the development and sale of nasal vaccines in Sweden. The company is developing nasal influenza vaccines, nasal vaccines for bird flu, nasal vaccines for pneumococcal disease such as pneumonia and meningitis. It offers vaccines for both children and adults.

Contact Information

Website
www.eurocine.se
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
SAT
Primary Office
  • Karolinska Institutet Science Park
  • Fogdevreten 2 Fogdevreten 2
  • 171 65 Solna
  • Sweden
+46 08-508 000 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eurocine Vaccines Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.47 $0.49 $0.47 - $1.90 $4.07M 8.9M 34K -$0.16

Eurocine Vaccines Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019 FY 2018 30-Jun-2018
EV 3,756 7,944 2,653 9,028
Revenue 0 0 0 0
EBITDA (1,654) (923) (2,279) (5,111)
Net Income (1,656) (956) (2,306) (5,111)
Total Assets 2,313 3,477 583 1,372
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eurocine Vaccines Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eurocine Vaccines‘s full profile, request access.

Request a free trial

Eurocine Vaccines Executive Team (2)

Name Title Board Seat Contact Info
Hans Arwidsson Ph.D Chief Executive Officer & President
Anna-Karin Maltais Chief Scientific Officer & Vice President, Research & Development
To view Eurocine Vaccines’s complete executive team members history, request access »

Eurocine Vaccines Board Members (1)

Name Representing Role Since
Pierre Morgon Self Board Member 000 0000
To view Eurocine Vaccines’s complete board members history, request access »

Eurocine Vaccines Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial